Liquidia (LQDA) Net Cash Flow Growth (1y) (2021 - 2026)
Liquidia (LQDA) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.20 Bn | 21.05 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.58 Bn | 12.15 Bn | 785.00 Mn | -1,020.00% |
| 10 | Liquidia | 7.61 Bn | 7.39 Bn | 121.79 Mn | 577.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 577.70% |
| Dec 31, 2025 | 218.99% |
| Sep 30, 2025 | -122.34% |
| Jun 30, 2025 | 128.94% |
| Mar 31, 2025 | -109.06% |
| Dec 31, 2024 | -474.15% |
| Sep 30, 2024 | 695.40% |
| Jun 30, 2024 | -298.41% |
| Mar 31, 2024 | 6,470.33% |
| Dec 31, 2023 | 247.98% |
| Sep 30, 2023 | -116.87% |
| Jun 30, 2023 | -113.50% |
| Mar 31, 2023 | 276.33% |
| Dec 31, 2022 | 23.22% |
| Sep 30, 2022 | -43.90% |
| Jun 30, 2022 | 223.06% |
| Mar 31, 2022 | 102.57% |
| Dec 31, 2021 | 53.91% |
| Sep 30, 2021 | -106.85% |
| Jun 30, 2021 | 186.17% |